

REFERENCES

- ACS, 2015. Nasopharyngeal Cancer. 3 March, pp. 01-44.
- ACS, 2015. Signs and Symptoms of Nasopharyngeal Cancer. 15 January.
- Adham, M. et al., 2012. Nasopharyngeal carcinoma in Indonesia: epidemiology, incidence, signs, and symptoms at presentation. *Chinese Journal of Cancer*, 31(4), pp. 185- 196.
- Adham, M. et al., 2014. Current status of cancer care for young patients with nasopharyngeal carcinoma in Jakarta, Indonesia. *PloS ONE*.
- Baer, R. et al., 1984. DNA Sequence and Expression of the B95-8 Epstein-Barr Virus Genome. *Nature*, pp. 207-211.
- Bardy, B., Morinet, F. & Perol, Y., 1989. Occurrence of Epstein-Barr virus deoxyribonuclease enzyme activity-neutralizing antibodies. An index of Epstein-Barr virus disease. *Intervirology*, 30(1), pp. 36-43.
- Baumforth, K. et al., 1999. The Epstein-Barr virus and its association with human cancers. *Molecular Pathology*, 52(6), pp. 307-322.
- Bhaduri-McIntosh, S. et al., 2007. Serum IgA Antibodies to Epstein-Barr Virus (EBV) Early Lytic Antigens Are Present in Primary EBV Infection. *The Journal of Infectious Diseases*, Volume 195, pp. 483-492.
- Bryant, H. & Farrell, P. J., 2002. Signal Transduction and Transcription Factor Modification during Reactivation of Epstein-Barr Virus from Latency. *Journal of Virology*, 76(20), pp. 10290-10298.
- Cao, S.-M. et al., 2011. Fluctuations of Epstein-Barr Virus Serological Antibodies and Risk for Nasopharyngeal Carcinoma: A Prospective Screening Study with a 20-Year Follow-Up. *PloS ONE*, 6(4).
- Chan, A., Teo, P. & Johnson, P., 2002. Nasopharyngeal carcinoma. *Annals of Oncology*, 13(7), pp. 1007-1015.
- Cheng, Y.-C., Chen, J.-Y., Glaser, R. & Henle, W., 1980. Frequency and levels of antibodies to Epstein-Barr virus-specific DNase are elevated in patients with nasopharyngeal carcinoma. *Medical Sciences*, 77(10), pp. 6162-6165.
- Chiang, A. K., Tao, Q., Srivastava, G. & Ho, F. C., 1996. Nasal NK-And T-Cell

- Lymphomas Share The Same Type of Epstein-Barr Virus Latency as Nasopharyngeal Carcinoma and Hodgkin's Disease. *International Journal of Cancer*; Volume 68, pp. 285-290.
- Connolly, Y. et al., 2001. Antibodies to Epstein-Barr virus thymidine kinase: A characteristic marker for the serological detection of nasopharyngeal carcinoma. *International Journal of Cancer*; Volume 91, pp. 692-697.
- Dorshkind, K. & Swain, S., 2009. Age-Associated Declines in Immune System Development and Function: Causes, Consequences, and Reversal. *Current Opinion in Immunology*, 21(4), pp. 404-407.
- Du, J.-L. et al., 2016. Subtype distribution and long-term titer fluctuation patterns of serum anti-Epstein-Barr virus antibodies in a non-nasopharyngeal carcinoma population from an endemic area in South China: a cohort study. *Chinese Journal of Cancer*, pp. 1-8.
- Fachiroh, J. et al., 2006. Single-Assay Combination of Epstein-Barr Virus (EBV) EBNA1- and Viral Capsid Antigen-p18-Derived Synthetic Peptides for Measuring Anti-EBV Immunoglobulin G (IgG) and IgA Antibody Levels in Sera from Nasopharyngeal Carcinoma Patients: Options for Field Scr. *Journal of Clinical Microbiology*, 44(4), pp. 1459-1467.
- Fachiroh, J. et al., 2004. Molecular Diversity of Epstein-Barr Virus IgG and IgA Antibody Responses in Nasopharyngeal Carcinoma: A Comparison of Indonesian, Chinese, and European Subjects. *The Journal of Infectious Diseases*, 190(1), pp. 53-62.
- Hammerschmidt, W. & Sugden, B., 2013. Replication of Epstein-Barr Viral DNA. *Cold Spring Harbor Perspectives in Biology*.
- Hao, S.-P., Tsang, N.-M. & Chang, K.-P., 2003. Screening nasopharyngeal carcinoma by detection of the latent membrane protein 1 LMP-1 gene with nasopharyngeal swabs. *Cancer*, 97(8), pp. 1909-1913.
- Hayes, D. et al., 1999. Expression of Epstein-Barr virus (EBV) transcripts encoding homologues to important human proteins in diverse EBV associated diseases. *Journal of Clinical Pathology*, Volume 52, pp. 97-103.
- Henle, G. & Henle, W., 1976. Epstein-barr virus-specific IgA serum antibodies as

- an outstanding feature of nasopharyngeal carcinoma. *International Journal of Cancer*, 17(1), pp. 1-7.
- Hislop, A. W., Taylor, G. S., Sauce, D. & Rickinson, A. B., 2007. Cellular Response to Viral Infection in Humans: Lessons from Epstein-Barr Virus. *The Annual Review of Immunology*, pp. 587-617.
- Jia, W.-H. & Qin, H.-D., 2012. Non-viral environmental risk factors for nasopharyngeal carcinoma: A systematic review. *Seminars in Cancer Biology*, 22(2), pp. 117-126.
- Ji, M. et al., 2007. Sustained elevation of Epstein-Barr virus antibody levels preceding clinical onset of nasopharyngeal carcinoma. *British Journal of Cancer*, 96(4), pp. 623-630.
- Kutok, J. & Wang, F., 2006. Spectrum of Epstein-Barr Virus-Associated Diseases. *The Annual Review of Pathology: Mechanism of Disease*, pp. 375-404.
- Lee, W. et al., 1997. Nasopharyngeal carcinoma: presenting symptoms and duration before diagnosis. *Hongkong Medical Journal*, pp. 355-361.
- Listi, F. et al., 2006. A Study of Serum Immunoglobulin Levels in Elderly Persons That Provides New Insights into B Cell Immunosenescence. *New York Academy of Sciences*, pp. 487-495.
- Litter, E. et al., 1986. Identification of an Epstein-Barr virus-coded thymidine kinase. *The EMBO Journal*, 5(8), pp. 1959-1966.
- Old, L. et al., 1966. Precipitating Antibody in Human Serum to an Antigen Present in Cultured Burkitts Lymphoma Cells. *Proceeding of the National Academy of Sciences of the United State of America*, 56(6), pp. 1699-1704.
- Paramita, D. K., Fachiroh, J., Armata, W. T. & Benthem, E. V., 2007. Native Early Antigen of Epstein-Barr Virus, A Promising Antigen for Diagnosis of Nasopharyngeal Carcinoma. *Journal of Medical Virology*, Volume 79, pp. 1710-1721.
- Razak, A. R. et al., 2010. Nasopharyngeal carcinoma: The next challenges. *European Journal of Cancer*, 46(11), pp. 1967-1978.
- Sample, J. et al., 1990. Epstein-Barr Virus Types 1 and 2 Differ in Their EBNA-3A, EBNA-3B, and EBNA-3C Genes. *Journal of Virology*, 64(9), pp. 4084-

4092.

- Tedeschi, R. et al., 1995. The disease associations of the antibody response against the Epstein--Barr virus transactivator protein ZEBRA can be separated into different epitopes. *Journal of General Virology*, 76(6), pp. 1393-1400.
- Thompson, M., 2004. Epstein-Barr Virus and Cancer. *Clinical Cancer Research*, 10(3), pp. 803-821.
- Tugizov, S. M., Berline, J. W. & Palefsky, J. M., 2003. Epstein-Barr virus infection of polarized tongue and nasopharyngeal epithelial cells. *Nature Medicine*, 9(3), pp. 307-314.
- Wan, J. et al., 2004. Elucidation of the c-Jun N-Terminal Kinase Pathway Mediated by Epstein-Barr Virus-Encoded Latent Membrane Protein 1. *Molecular and Cellular Biology*, 24(1), pp. 192-199.
- Wei, W. I. & Sham, J. S., 2005. Nasopharyngeal carcinoma. *Lancet*, Volume 365, pp. 2041-2054.
- WHO, 2014. Nasopharyngeal Carcinoma. *Review of Cancer Medicines on the WHO List of Essential Medicine*.
- Young, L. S. & Dawson, C. W., 2014. Epstein-Barr virus and nasopharyngeal carcinoma. *Chinese Journal of Cancer*.
- Yu, M. & Yuan, J., 2002. Epidemiology of nasopharyngeal carcinoma. *Seminars in Cancer Biology*, 12(6), pp. 421-429.